Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Back

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Bristol Taunton Liverpool Swansea Cambridge Coventry London

Medical Conditions

Obesity

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by chance and is not known by participants or the study doctor. In the extension phase participants will get either CagriSema or slowly reduce participants dose of CagriSema if participants had CagriSema in the main phase. Which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. If participants had "dummy medicine" in the main phase, participants will get CagriSema in the extension phase. Like all medicines, the study medicine may have side effects.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Feb 2025 Aug 2028

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Participants will receive cagrilintide subcutaneously.

Intervention Arm Group : CagriSema;

Intervention Type : DRUG
Intervention Description : Participants will receive semaglutide subcutaneously.

Intervention Arm Group : CagriSema;

Intervention Type : DRUG
Intervention Description : Participants will receive placebo matched to cagrilintide subcutaneously.

Intervention Arm Group : Placebo;

Intervention Type : DRUG
Intervention Description : Participants will receive placebo matched to semaglutide subcutaneously.

Intervention Arm Group : Placebo;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Southmead Hospital
    Bristol
    BS10 5NB
  • Musgrove Park Hospital
    Taunton
    TA1 5DA
  • Aintree University Hospital
    Liverpool
    L9 7AL
  • Joint Clinical Research Facility - Swansea
    Swansea
    SA2 8PP
  • Addenbrooke's Hospital_Cambridge
    Cambridge
    CB2 0QQ
  • University Hospital Coventry - WISDEM Centre
    Coventry
    CV2 2DX
  • Royal London Hospital - Blizard Institute
    London
    E1 2AJ


The study is sponsored by Novo Nordisk A/S



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06780449
Last updated 16 January 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top